What are the main factors affecting the outcome of tocilizumab therapy in COVID-19-induced cytokine release syndrome?
Main Authors: | Cansu Akleylek, Seray Gizem Gür, Ibrahim Halil Sever, Safiye Koçulu Demir, Esin Cevik, Egemen Eken, Zafer Gökkaya, Yonca Çağatay, Neslihan Yılmaz |
---|---|
Format: | Article |
Language: | English |
Published: |
AVES
2022-07-01
|
Series: | European Journal of Rheumatology |
Online Access: | https://www.eurjrheumatol.org/en/what-are-the-main-factors-affecting-the-outcome-of-tocilizumab-therapy-in-covid-19-induced-cytokine-release-syndrome-133435 |
Similar Items
-
Quinolone resistance of gram negative bacteria from the patients with malignancies and relationship with prophylaxis
by: Nur Efe Iris, et al.
Published: (2016-09-01) -
The Evaluation of Clostridium difficile Toxin A ve B Positivity Rates and Epidemiological Characteristics in Febrile Neutropenic Patients with Diarrhea
by: Nur EFE İRİS, et al.
Published: (2015-12-01) -
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
by: Neven Mohamed Sarhan, et al.
Published: (2023-04-01) -
Successful Treatment of Disseminated Fusariosis with the Combination of Voriconazole and Liposomal Amphotericin B
by: Nur Efe İris, et al.
Published: (2016-11-01) -
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)